Novartis completes acquisition of Tourmaline Bio
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Subscribe To Our Newsletter & Stay Updated